Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1770-1776

  Beeghly Fadiel, Alicia ^a   Lu, Wei ^b   Long, Ji Rong ^a   Shu, Xiao Ou ^a   Zheng, Ying ^b   Cai, Qiuyin ^a   Gao, Yu Tang ^b   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REGISTRIES;

EID: 67449093692     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0125     Document Type: Article

References (40)

1. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69. (Pubitemid 40720240)
2. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005;87:287-297
3. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34. (Pubitemid 43723979)
4. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-257
5. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-970 (Pubitemid 32706688)
6. Moon A, Kim MS, Kim T G, et al. H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 2000;85:176-181 (Pubitemid 30023064)
7. Baruch RR, Melinscak H, Lo J, Liu Y, Yeung O, Hurta RAR. Altered matix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Bio Int 2001;25:411-420 (Pubitemid 32530353)
8. Cockett MI, Murphy G, Birch ML, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998;63:295-313. (Pubitemid 128669571)
9. Tester AM, Waltham M, Oh SJ, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 2004;64:652-658 (Pubitemid 38120906)
10. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051 (Pubitemid 28182477)
11. Brummer O, Athar S, Riethdorf L, Loning T, Herbst H. Matrix- metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999;435:566-573
12. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 2002;55:300-304 (Pubitemid 35193256)
13. Lebeau A, Muller-Aufdemkamp C, Allmacher C, et al. Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth. J Mol Histol 2004;35:443-455 (Pubitemid 41410960)
14. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-7628 (Pubitemid 39557525)
15. Fujiwara A, Shibata E, Terashima H, et al. Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast Cancer 2006;13:272-278
16. Garbett EA, Reed MW, Stephenson TJ, Brown NJ. Proteolysis in human breast cancer. Mol Pathol 2000;53:99-106. (Pubitemid 30183084)
17. Hanemaaijer R, Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000;86:204-207 (Pubitemid 30180815)
18. LaRocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90:1414-1421 (Pubitemid 38586271)
19. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-7558 (Pubitemid 37392068)
20. Vasku V, Vasku A, Tschoplova S, Izakovicova HL, Semradova V, Vacha J. Genotype association of C(-735)Tpo lymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 2002;204:262-265
21. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional Haplotypes in the Promoter of Matrix Metalloproteinase-2 Predict Risk of the Occurrence and Metastasis of Esophageal Cancer. Cancer Res 2004;64:7622-7628 (Pubitemid 39372109)
22. Roehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS. Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 2007;102:123-124 (Pubitemid 46294954)
23. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008;65:68-72.
24. Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004;25:399-404. (Pubitemid 38344407)
25. Lei H, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007;103:61-69 (Pubitemid 46653260)
26. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000;87:295-300. (Pubitemid 30434361)
27. Beeghly-Fadiel A, Long JR, Gao YT, et al. Common MMP-7 polymorphisms and breast cancer susceptibility: A multistage study of association and functionality. Cancer Res 2008;68:6453-6459
28. Ye C, Dai Q, Lu W, et al. Two-stage case-control study of common ATM gene variants in relation to breast cancer risk. Breast Cancer Res Treat 2007;106:121-126 (Pubitemid 47498090)
29. The International HapMap Project. Nature 2003;426:789-796
30. de Bakker PIW, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006;38:1166-1172 (Pubitemid 44470362)
31. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: Over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 2005;15:269-275 (Pubitemid 40309391)
32. Yang G, Gao YT, Cai QY, Shu XO, Cheng JR, Zheng W. Modifying effects of sulfotransferase 1A1 gene polymorphism on the association of breast cancer risk with body mass index or endogenous steroid hormones. Breast Cancer Res Treat 2005;94:63-70. (Pubitemid 41416943)
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265 (Pubitemid 40202029)
34. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 2005;29:299-312. (Pubitemid 41720949)
35. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996;93:7069-7074 (Pubitemid 26243503)
36. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 {β} by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1{β} processing. J Immunol 1998;161:3340-3346 (Pubitemid 128470627)
37. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem J 1997;322:809-814 (Pubitemid 27135628)
38. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-29137 (Pubitemid 29477077)
39. Kim ES, Sohn YW, Moon A. TGF-[β]-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Lett 2007;252:147-156 (Pubitemid 46738609)
40. Song H, Ki SH, Kim SG, Moon A. Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res 2006;66:10487-10496 (Pubitemid 44799770)